According to the data released by China National Bureau of Statistics on July 27, in the first half of 2021, China's pharmaceutical manufacturing industry achieved a year-on-year increase of 28.0% in operating income to 1,404.69 billion Yuan, and realized a total profit growth of 88.8% year-on-year to 300.04billion Yuan.
Among them, several Chinese major pharmaceutical companies have also delivered very good results. For example, Harbin Pharmaceutical Group achieved a year-on-year increase of 33.19% in operating income to 6.406 billion Yuan, of which the main business income of the pharmaceutical industry was 1.742 billion Yuan, the main business income of the pharmaceutical business was 4.664 billion Yuan, and the net profit in the first half of the year was 366 million Yuan. A year-on-year increase of 677 million Yuan; net profit attributable to shareholders of listed companies was 342 million Yuan; net profit attributable to shareholders of listed companies deducting non-recurring gains and losses was 200 million Yuan, a year-on-year increase of 557 million Yuan. Judging from the company's semi-annual report data, Harbin Pharmaceutical Group has made considerable progress in its performance. Lifeon Pharmaceutical also achieved a double increase in revenue and net profit. Lifeon Pharmaceutical’s revenue in the first half of the year increased by 20.38% year-on-year to 1.074 billion Yuan; net profit attributable to shareholders of listed companies increased by 26.55% year-on-year to 83.584 million Yuan. The pharmaceutical industry segment achieved business Revenue increased by 59% year-on-year to 428 million Yuan, and gross profit margin reached 89.36%, an increase of 1.90% over the same period last year. Neptunus Biology also issued a semi-annual report stating that in the first half of 2021, its operating income increased by 13.28% year-on-year to approximately 20.238 billion Yuan. The net profit attributable to shareholders of listed companies increased by 9.44% year-on-year to approximately 140 million Yuan. Tibet Pharmaceuticals issued a semi-annual report, stating that in the first half of 2021, operating income increased by 65.13% year-on-year to approximately 1.038 billion Yuan. Net profit attributable to shareholders of listed companies increased by 35.62% year-on-year to approximately 298 million Yuan.
In addition, in many Chinese traditional medicine area, many companies also submitted satisfactory answers in the first half of the year. For example, in the first half of 2021, KPC Group realized a year-on-year increase of 19.54% in operating income to 4.093 billion Yuan; realized a net profit attributable to shareholders of listed companies increased by 47.84% year-on-year to 332 million Yuan. In the first half of the year, Zhongxin Pharmaceuticals achieved a year-on-year increase of 10.64% in operating income to 3.64 billion Yuan; net profit attributable to shareholders of the parent company increased by 43.00% year-on-year to 463 million Yuan.
The vigorous development of the pharmaceutical industry has also brought about the rapid development of the upstream pharmaceutical machinery industry. According to the 2021 semi-annual performance survey of major pharmaceutical machinery companies, many companies have continued to increase their performance. For example, One of IVEN cooperator Kinglai Group which is the top brand of clear class material company , has increased by 71.82%-101.44% over the same period of the previous year.
From the perspective of pharmaceutical machinery industry environment in the first half of 2021, there are many favorable factors, such as the continuous expansion of equipment production demand, technological advancement, the integrity of the supply chain are less affected by the Covid-19 epidemic, and the delivery date of imported equipment due to the current epidemic unable to meet the needs of pharmaceutical companies, the domestic pharmaceutical equipment industry has ushered in huge development opportunities. On the other hand, opportunities and challenges coexist, and development also faces more challenges at this year. For example, our company IVEN Pharmatech is progressing in development, and it is also facing rising steel material price index and labor cost as it is difficult to get suitable flights abroad, and the isolation period also brings challenges in cost control. However, with the progress of the overall domestic science and technology, IVEN continues to deepen its technology and services. In terms of equipment quality, it adheres to the concept of quality first, continuously innovates, and improves equipment remoteness, operational stability, intelligence, and automation, while overcoming numerous problems, help customers to successfully install projects, help domestic and foreign customers to achieve stable and more efficiency production, and reduce costs and labor dependence, speed up project construction. Finally like our company mission, create value for customers, and we hope to create MORE.
